Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Peter, Szakaly"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Malika Cremer, Ahmed Shoker, Claudia Sommerer, Helio Tedesco-Silva, Philippe Lang, Hartmut W. Mayer, Abdel Hmissi, Peter Szakaly, Norio Yoshimura, Francesco Paolo Schena
Publikováno v:
Transplantation. 84:885-892
Background FTY720 is a novel immunomodulator that was developed to produce optimal graft protection with improved safety and tolerability. Phase II studies have demonstrated the efficacy of FTY720 up to the doses of 2.5 mg with full-dose cyclosporine
Autor:
Adam, Varga, Barbara, Sandor, Karoly Kalmar, Nagy, Dora, Praksch, Katalin, Gombos, Andras, Toth, Kalman, Toth, Peter, Szakaly
Publikováno v:
In vivo (Athens, Greece). 29(2)
Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenom
Autor:
Adam, Varga, Barbara, Sandor, Karoly Kalmar, Nagy, Maria, Viola, Andras, Toth, Katalin, Gombos, Kalman, Toth, Peter, Szakaly
Publikováno v:
In vivo (Athens, Greece). 29(1)
Cardiovascular diseases are a leading cause of mortality after kidney transplantation. According to guidelines, acetylsalicylic acid (ASA) must be given as preventive antiplatelet therapy, but resistance to this drug is also well-known.A total of 214